Nurix Therapeutics Q3 2023 Earnings Report $19.83 -0.21 (-1.05%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPS-$0.68Consensus EPS -$0.84Beat/MissBeat by +$0.16One Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual Revenue$18.47 millionExpected Revenue$19.98 millionBeat/MissMissed by -$1.51 millionYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ3 2023Date10/12/2023TimeQ3 2023 Earnings ReleaseConference Call ResourcesPress ReleaseSEC FilingNRIX Earnings HistoryPowered by AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Nurix Therapeutics Earnings HeadlinesNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.35 Consensus Target Price from AnalystsDecember 20 at 1:24 AM | americanbankingnews.comNurix Therapeutics receives U.S. FDA Fast Track designation for NX-5948December 19 at 1:21 PM | markets.businessinsider.comI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. December 21, 2024 | Porter & Company (Ad)Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s MacroglobulinemiaDecember 19 at 8:19 AM | finance.yahoo.comNurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's MacroglobulinemiaDecember 19 at 7:00 AM | globenewswire.comBuy Rating Reaffirmed for Nurix Therapeutics: Promising Clinical Data and Increased Approval Probability for NX-5948December 12, 2024 | markets.businessinsider.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX), a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
